In reply to 'Pre-screening with GeneXpert® MTB/RIF may increase use of isoniazid preventive therapy in antiretroviral programmes'

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 9, 2011, Pages 1273-1274

  Fenner, Lukas ^a   Boulle, Andrew ^b   Egger, Matthias ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ANTIVIRAL THERAPY; DIAGNOSTIC VALUE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; LETTER; LOWEST INCOME GROUP; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SCREENING TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 80051691991     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0407-2     Document Type: Letter

References (4)

1. Fenner L, Forster M, Egger M, and others, for the ART-LINC collaboration of IeDEA. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis 2011; 15: 620-627.
2. World Health Organization. Guidelines for intensifi ed tuberculosis case-fi nding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO, 2011.
3. Pewsner D, Battaglia M, Minder C, Marx A, Bucher H C, Egger M. Ruling a diagnosis in or out with 'SpPIn' and 'SnNOut': a note of caution. BMJ 2004; 329: 209-213. (Pubitemid 39013280)
4. Egger M, Ekouevi D K, Williams C, et al. Cohort profi le: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2011. http://dx.doi.org/ 10.1093/ije/dyr080 (epub ahead of print).